Tigecycline: A review of a new glycylcycline antibiotic

@article{Scheinfeld2005TigecyclineAR,
  title={Tigecycline: A review of a new glycylcycline antibiotic},
  author={Noah S. Scheinfeld},
  journal={Journal of Dermatological Treatment},
  year={2005},
  volume={16},
  pages={207 - 212}
}
  • N. Scheinfeld
  • Published 1 January 2005
  • Medicine
  • Journal of Dermatological Treatment
Tigecycline derived from minocycline. It is part of a new class of antibiotics called glycylcyclines. Tigecycline is given intravenously and has activity against a variety of gram‐positive and gram‐negative bacterial pathogens, many of which are resistant to existing antibiotics. Tigecycline successfully completed phase III trials in which it was at least equal to intravenous vancomycin and aztreonam to treat complicated skin and skin structure infections (cSSSI), and to intravenous imipenem… 

The recent evolution of therapeutic weapons

  • Medicine, Biology
  • 2015
The main problems related to the epidemiology of multiresistant gram-positive infection, the potential clinical indications of all recently available compounds compared with the standard of care of treatment of resistant Gram-positive infections, and updated data on efficacy and tolerability of all these compounds are updated and outlined on the ground of a review of recent literature evidences.

Management of complicated infections in the era of antimicrobial resistance: the role of tigecycline

Tigecycline is a novel extended-spectrum minocycline derivative that circumvents bacterial resistance, as it is unaffected by efflux pumps and ribosomal protection but should not be used as empiric monotherapy for treatment of health-care associated infections known or suspected to be owing to Pseudomonas aeruginosa or Proteus spp.

The recent evolution of therapeutic weapons against resistant Gram-positive microorganisms La evolución reciente de las armas terapéuticas contra los microorganismos Gram-positivos

The main problems related to the epidemiology of multiresistant gram-positive infection, the potential clinical indications of all recently available compounds compared with the standard of care of treatment of resistant Grampositive infections, and updated data on efficacy and tolerability of all these compounds, are updated and outlined on the ground of a review of recent literature evidences.

LEUKOPENİA RELATED TO TİGECYCLİNE USE FOR DİABETİC FOOT INFECTİON: CASE REPORT

Knowing the adverse effects of antibiotics chosen for treatment of diabetic foot infection is as important as choosing the appropriate antibiotic according to antibiograms.

Emergence of In-Vitro Colistin and / or Tigecycline resistance among Carbapenemase producing Gram negative Bacteria in nosocomial set up

The drug susceptibility pattern of carbapenemase producing gram negative bacteria causing various nosocomial infections was record to record to identify strains resistant to Tigecycline and/or Colistin and those susceptible to Polymyxin-B.

Non-antimicrobial strategies for the prevention and treatment of infections by multidrug-resistant gram-negative bacilli

In vivo, AOA-2 in combination with colistin reduced bacterial spleen and lung loads, bacteremia and mortality rates, in comparison with the monotherapy with colistsin, and in vivo, the therapeutic efficacy of Aoa-2 against A. baumannii and P. aeruginosa in experimental murine models of peritoneal sepsis and pneumonia was evaluated.

Tetracyclines: what a rheumatologist needs to know?

  • S. Attar
  • Medicine
    International journal of rheumatic diseases
  • 2009
The rheumatological use of tetracycline and its analogues in rheumatic diseases is reviewed.

Efficacy of Tigecycline as Salvage Therapy in Multidrug-Resistant Febrile Neutropenia in Patients with Acute Leukemia—A Single Center Analysis

Evaluated the efficacy of tigecycline treatment in comparison to standard treatment in patients with acute leukemia and diagnosis of febrile neutropenia resistant to hospital-based multidrug escalation levels, and observed comparable overall response rates.

References

SHOWING 1-10 OF 40 REFERENCES

Activities of the Glycylcycline Tigecycline (GAR-936) against 1,924 Recent European Clinical Bacterial Isolates

The new glycylcycline exhibited excellent activity against all gram-positive cocci and was also very potent against most members of the Enterobacteriaceae.

In Vitro Activities of Tigecycline against the Bacteroides fragilis Group

Tigecycline was more active than clindamycin, minocycline, trovafloxacin, and cefoxitin and less active than imipenem or piperacillin-tazobactam against all isolates of the B. fragilis group.

Activity of Tigecycline (GAR-936) against Acinetobacter baumannii Strains, Including Those Resistant to Imipenem

These in vitro results show that tigecycline has good in vitro bacteriostatic activity against A. baumannii, including strains resistant to imipenem.

The glycylcyclines: a comparative review with the tetracyclines.

Tigecycline appears to be a promising new antibacterial based on in vitro and pharmacokinetic/pharmacodynamic activity; however more clinical data are needed to fully evaluate its potential.

In Vitro Activities of Tigecycline (GAR-936) and 12 Other Antimicrobial Agents against 90 Eikenella corrodens Clinical Isolates

ABSTRACT The activity of tigecycline was compared with those of other antimicrobials against 90 isolates of Eikenella corrodens. The MIC at which 90% of the isolates were inhibited was 2 μg/ml for

In Vitro Activities of Tigecycline against Erythromycin-Resistant Streptococcus pyogenes and Streptococcus agalactiae: Mechanisms of Macrolide and Tetracycline Resistance

Tigecycline proved to be very active against all the isolates tested, including those resistant to tetracycline, including the resistant to erythromycin-resistant streptococci.

Pharmacokinetics of Tigecycline after Single and Multiple Doses in Healthy Subjects

Tigecycline exhibits linear pharmacokinetics and is safe and well tolerated in the dose ranges examined, and side effects, mainly nausea and vomiting, were seen in these studies.

Approaches to vancomycin-resistant enterococci.

Treatment of vancomycin-resistant enterococci continues to be problematical although these new drugs offer some hope, and the rational use of antibiotics, strict guidelines for the use of new compounds, and adherence to infection control practices continue to be essential components of the management ofVancomycus-resistantEnterococci colonization and infection.